Calidi Biotherapeutics (CLDI) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Calidi Biotherapeutics is the larger company by market cap ($3.9 million vs $3.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | VIVS |
|---|---|---|
| Share price | $1.05 | $0.1819 |
| Market cap | $3.86M | $3.02M |
| 1-day change | +0.96% | +2.65% |
| EPS (TTM) | $-36.47 | $-4.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $3.41 |
| 52-week low | $0.986 | $0.1681 |
| Distance from 52-week high | -96.23% | -94.67% |
| Average volume | 255.53K | 5.85M |
| Shares outstanding | 3.68M | 16.59M |
| Employees | 29 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
CLDI vs VIVS FAQ
Which is bigger, Calidi Biotherapeutics or VivoSim Labs?
Calidi Biotherapeutics (CLDI) is larger, with a market capitalization of $3.86M compared with $3.02M for VivoSim Labs (VIVS).
Are Calidi Biotherapeutics and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.